| |
NMR in Biomedicine, Vol. 12, No. 3. (1999), pp. 123-138.
|
| |
Cancer Imaging, Vol. 6 (2006), pp. 95-99.
|
| |
Clin Cancer Res, Vol. 8, No. 9. (1 September 2002), pp. 2766-2774.
|
| |
Seminars in Nuclear Medicine In Impact of FDG-PET Imaging on the Practice of Medicine, Vol. 32, No. 1. (January 2002), pp. 35-46.
|
| |
The Lancet Oncology, Vol. 5, No. 9. (September 2004), pp. 531-540.
|
| |
J Nucl Med, Vol. 43, No. 8. (1 August 2002), pp. 1018-1027.
|
| |
European Journal of Cancer and Clinical Oncology, Vol. 25, No. 1. (January 1989), pp. 123-128.
|
| |
Eur J Nucl Med Mol Imaging, Vol. 33 Suppl 13 (July 2006), pp. 11-15.
|
| |
Annu Rev Med, Vol. 57 (2006), pp. 99-118.
|
| |
Mol Imaging, Vol. 3, No. 1. (January 2004), pp. 1-8.
|
| |
Nat Rev Cancer, Vol. 2, No. 1. (January 2002), pp. 11-18.
|
| |
Anticancer Drugs, Vol. 6, No. 3. (June 1995), pp. 443-450.
|
| |
Cancer J, Vol. 9, No. 1. (b 2003), pp. 33-41.
by T. A. Buchholz, D. W. Davis, D. J. McConkey, et al.W. F. Symmans, V. Valero, A. Jhingran, S. L. Tucker, L. Pusztai, M. Cristofanilli, F. J. Esteva, G. N. Hortobagyi, A. A. Sahin
|
| |
Lancet, Vol. 349, No. 9055. (22 March 1997)
|
| |
Radiother Oncol, Vol. 46, No. 2. (February 1998), pp. 185-191.
|
| |
Cancer, Vol. 89, No. 11. (2000), pp. 2145-2152.
|
